Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2024-02-14

Clinical Trial Update: Fatty Acid Amide Hydrolase (FAAH) Inhibitor Treatment of Cannabis Use Disorder (CUD) [Phase 2]

View source ↗

Summary

Phase 2 trial update on a fatty acid amide hydrolase (FAAH) inhibitor for Cannabis Use Disorder has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • FAAH-inhibitor

Snippet

Sponsor: Yale University | Conditions: Cannabis Use Disorder | Phase 2 | Status: COMPLETED | Results posted: 2024-02-14